Robert Andrews
ADC & Conjugate Patent Strategy (European Patent Attorney) Mewburn Ellis LLP
Robert is one of Europe’s leading patent attorneys specialising in antibody-drug conjugates (ADCs), non-traditional conjugates and targeted therapeutic platforms. He has more than 20 years’ experience advising founders, executives, and in-house IP teams of ADC and conjugate life science companies. Over this time, he has built a reputation as a trusted advisor on European ADC intellectual property and patent strategy, noted for providing practical, commercial insights grounded in deep technical understanding and long experience working with start ups, SMEs, and international biotechs.
Robert has worked closely with ADC and conjugate clients on ADC patent strategy, prosecution, FtO, EPO oppositions, due diligence and transactions to build value in conjugate assets that withstand investor, partner, and regulatory scrutiny. Working with innovators ranging from venture-backed start-ups to commercial-stage organisations, he combines deep scientific understanding with commercially focused ADC patent strategy to help clients create, protect and maximise the value of their intellectual property assets.
Seminars
In today’s increasingly crowded ADC landscape, savvy IP strategy is critical for commercial success. This workshop explores how innovators can identify the IP opportunities and risks when developing a novel conjugate asset. Gain practical insights into competitive IP positioning, covering the type and timing of your own IP creation, as well as how to manage freedom-to-operate challenges. The workshop will demonstrate how to use IP strategy to enable your ADC or conjugate asset to reach its full commercial potential.
Key Questions:
- Review approaches for leveraging known technology to minimise patent infringement risk
- Understand the risks and opportunities of using known technology as the starting point for innovation
- Explore strategies for protecting novel ADC assets and position them to withstand competitive challenges
